Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026 (Adrià Calatayud/Wall Street Journal)

Adrià Calatayud / Wall Street Journal : Swiss pharmaceutical group Roche agrees to acquire US-based PathAI, which makes AI diagnostic tools, for up to $1.05B, with $750M upfront, closing in H2 2026 —  The pharma giant has agreed to pay $750 million upfront, with up to $300 million in additional payments subject to targets

Go to News Site